Invokana bags FDA approval
The treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes.
Read More
Tag: hospitalisation
Farxiga cuts hospitalisation for heart failure or CV death, study shows
AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
